RESUMEN
The primary in vitro antibody response to the type 2 antigen, trinitrophenyl (TNP)-Ficoll, is controlled by two complementing loci in the H-2 region of the mouse major histocompatibility complex (MHC). High responder alleles at both loci are necessary for a high responder phenotype. Previous studies mapped one locus of control to the I-A subregion. In this report we demonstrate by recombinant analysis that the second locus of control is located between the H-2S and D regions. A comparison of responses in the B10.BAR6, B10.BAR10, and B10.BAR11 strains defined a locus controlling the response to TNP-Ficoll in a single haplotype, bounded on the left by the crossover event in the B10.BAR10 and on the right by the crossover event in the B10.BAR6 strain. A monoclonal antibody directed against this right-hand region of control has been produced (48.21.7) that blocks the response to TNP-Ficoll at the level of the antigen-presenting cell. The monoclonal antibody 48-21.7 is specific for the high responder b allele at the right-hand locus and did not inhibit responses to other protein antigens tested. The immune response to TNP-Ficoll was not inhibited by monoclonal antibodies that react with H-2Db or Qa-2 specificities, suggesting that the TNP-Ficoll response is controlled by a unique locus located between H-2S and D. Finally, 48-21.7 recognizes and precipitates a unique product of approximately 40,000 mol wt that is distinct from the H-2D region product recognized by the monoclonal antibody B22/249.
Asunto(s)
Formación de Anticuerpos , Genes MHC Clase II , Antígenos H-2/genética , Linfocitos/inmunología , Complejo Mayor de Histocompatibilidad , Animales , Anticuerpos Monoclonales , Células Cultivadas , Células Clonales , Femenino , Hemólisis , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos , Bazo/inmunologíaRESUMEN
Experience with 35 second grafts included in a total number of 310 renal transplants was analyzed to identify factors associated with success. The 2 year life-table renal survival rate of sequential cadaveric grafts is 42 percent compared in 54 percent for primary cadaveric grafts. The 2 year life-table patient survival rate for the same group is 68 percent compared to 72 percent for single cadaveric homotransplants. Twenty-one of 30 patients tested in the interval between grafts developed cytotoxic antibodies to greater than 5 percent of a random panel of cells; 43 percent of these kidneys functioned at least one year; 65 percent functioned for one year or more if the cytotoxicity was 5 percent or less. If the first graft functioned greater than 3 months, the second had a 67 percent chance of functioning for one year; if less than 3 months, the second had a 45 percent one year function rate. Removal of the first transplant at time of second transplantation resulted in an 88 percent one year life-table survival rate of the second kidney in nine patients. Removal prior to second transplantation resulted in a 25 percent one year survival rate in 23 patients. To further evaluate this significant finding, data was obtained through the American College of Surgeons/National Institutes of Health (ACS/NIH) Organ Transplant Registry from five major transplant centers. Thirty-two patients had their first graft removed at time of second transplantation with a 52 percent one year life-table kidney survival rate vs. 29 percent if the first were removed more than 90 days prior to second grafting. Statistical analysis shows this to be significant at the 95 percent confidence level.
Asunto(s)
Rechazo de Injerto , Trasplante de Riñón , Formación de Anticuerpos , Pruebas Inmunológicas de Citotoxicidad , Antígenos de Histocompatibilidad , Prueba de Histocompatibilidad , Humanos , Pronóstico , Estudios Retrospectivos , Factores de Tiempo , Supervivencia TisularRESUMEN
We have demonstrated in an anti-Ia serum the presence of specific antibodies reacting with T cells, as well as with B cells, using a highly sensitive dye exclusion test. This antiserum reacts with both spleen and lymph node in a characteristic biphasic titration curve killing up to 70% of these cells. It also reacts with cortisone-resistant thymocytes. The A.TH-alpha-A.TL serum can be absorbed with spleen, lymph node, cortisone-resistant thymus, or normal thymus cells. Further in vivo absorptions in BALB/c nude cannot remove all of the cytotoxic activity for normal BALB lymph node lymphocytes, while completely removing the activity for nude cells. A Thy-1 positive cell line derived from a C57Br leukemia is reactive with this anti-Ia serum.